Introduction
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a regulatory role in cholesterol homeostasis by promoting low-density lipoprotein receptor (LDLr) degradation. Thus, PCSK9 inhibition has emerged as a novel drug therapy to treat hypercholesterolaemia and related cardiovascular diseases. 1 Although the vast majority of the studies have focused on the role of PCSK9 in LDLr expression in the liver, an increasing body of evidence suggests that PCSK9 gene is also present in extra-hepatic tissues. 2 Recent studies showed that PCSK9 is highly expressed in vascular smooth muscle cells, and its expression is regulated by lipopolysaccharide, tumour necrosis factor a (TNF-a), reactive oxygen species (ROS), and damaged mitochondrial DNA. [3] [4] [5] Autophagy is a self-degradative process in response to stress, plays a critical role in balancing sources of energy and removing misfolded proteins, and is considered a protective and adaptive mechanism to promote cell survival under normal conditions. 6, 7 In the heart, some level of autophagy is observed at baseline, and its expression is up-regulated in response to pathological stimuli such as myocardial ischaemia. 8, 9 . Matsui et al. 10 studied the role of autophagy in the heart during ischaemia and showed that autophagy may be protective during ischaemia, but detrimental during reperfusion. Recent studies have shown that autophagy is activated in vascular smooth muscle cells and cardiomyocytes early in response to hypoxia, pro-inflammatory cytokines, and angiotensin II. 11, 12 Inflammation, particularly in the border zone (between the infarct area and the normal healthy zone), is a prominent feature of myocardial ischaemia and reflects an early response to injury. Pro-inflammatory cytokines, such as TNF-a, can cause additional injury to the cardiomyocytes. 8, 13, 14 In keeping with this concept, blockade of inflammatory mediators has been shown to limit ischaemic injury in experimental models of myocardial ischaemia. 15 In recent studies, we showed that lipopolysaccharide, a well-known mediator of inflammation, induces PCSK9 release and simultaneously development of autophagy in vascular smooth muscle cells. [3] [4] [5] 11 Although autophagy is known to be triggered by hypoxia or inflammation triggers, 16 it is unknown if hypoxia per se stimulates PCSK9 expression/secretion. We postulated that PCSK9 expression/secretion and development of autophagy during hypoxia may be a part of the dynamic changes at cellular levels occurring in the ischaemic heart. In this study, we show for the first time that ischaemic mouse hearts express PCSK9. We postulated that PCSK9 released during ischaemia determines infarct size and cardiac contractile function and is involved in the development of autophagy. , and LDLr -/-mice on the C57BL/ 6J background were purchased from Jackson Laboratories (Sacramento, CA, USA) and housed in the animal care facility of our institution. Mice were sacrificed by intra-peritoneal injection of pentobarbital (60 mg/kg). All experimental procedures were performed in accordance with protocols approved by the Institutional Animal Care and Usage Committee and conformed to the Guidelines for the Care and Use of Laboratory Animals published by the US National Institutes of Health. To avoid the effect of sex on PCSK9 levels, only male mice approximately 8 weeks of age were used in this study.
Materials and methods

Animals
To study the effect of PCSK9 on infarct size, cardiac contractile function, and development of autophagy, WT mice were daily treated with two different PCSK9 inhibitors Pep2-8 (10 mg per mouse/day, intravenously) or EGF-A-based inhibitor (20 mg per mouse/day, intravenously via tail vein) or saline (control). Two hours later, mice were subjected to myocardial ischaemia for 1 week.
Myocardial ischaemia protocol
The methodology for induction of myocardial ischaemia has been described earlier. 17 In brief, animals were anaesthetized with ketamine hydrochloride (60 mg kg -1 ) and xylazine hydrochloride (8 mg kg -1 ) intraperitoneally. After endotracheal intubation, mice were mechanically ventilated (tidal volume, 1.2 mL min -1 and respiration rate, 110 min).
Body temperature was maintained between 37.0 C and 37.5 C with a heating pad. Electrocardiogram was recorded throughout the experiment. After equilibration period of 5 min, under aseptic conditions, left thoracotomy was performed in the fourth intercostal space and the pericardium opened. An 8-0 silk suture was passed around the left coronary artery (LCA) at a point two-third of the way between its origin near the pulmonary conus. Occlusion of the LCA caused epicardial cyanosis with regional hypokinesia and electrocardiogram changes typical of acute myocardial infarction. Another group of animals underwent the same procedure, but without LCA ligation (sham ischaemia). The thoracic cavity was closed in layers, using 6-0 sutures, and drained to prevent pneumothorax. Endotracheal tube was then removed and animals allowed to recover.
Echocardiographic assessment of left ventricular function
Seven animals in each group were used to assess left ventricular (LV) function by echocardiography. At baseline and at 1, 2, 3, and 4 weeks post-LCA ligation, the mice were transferred to the warm platform of a 707 ultrasound system (Visual-Sonics Inc.). B-mode and M-mode echocardiography were performed, and LV fractional shortening was quantified as: (LVIDd -LVIDs)/LVIDd Â 100%, where LVIDd and LVIDs are left ventricular internal diameters during end-diastole and end-systole, respectively. All measurements represent the mean of at least 10 consecutive cardiac cycles.
Determination of infarct size
After echocardiography, the hearts were arrested by injection of 10% potassium chloride through the carotid artery, then excised, and fixed in 10% formalin. Some hearts were embedded in paraffin and cut serially from the apex to the base. Multiple 5 lm thick sections of the hearts were stained with haematoxylin and eosin (H&E). The infarcted area was measured using a quantitative digital image analysis system (Image-Pro Plus 6.0, Media Cybernetics). The infarct size based on at least five sections in each heart was expressed as a percentage of the total LV area. All sections were prepared by the same individual with attention to consistency in sectioning the hearts from different mice.
Studies in primary mouse cardiomyocytes
Hearts of neonatal mice were aseptically removed from the chest cavity and washed twice in PBS on ice. Hearts were then minced into small 0.5-to 1-mm pieces and trypsinized for 30 min in an incubator at 37 C. After trypsinization, heart fragments were passed five to six times through a 5 mL pipet every 10 min to facilitate the release of cells. Suspensions of cells were centrifuged at 800 g for 6 min, and the pellet was resuspended in DMEM containing 20% FBS and penicillin-streptomycin (ATCC). Cells were plated on a six-well plate with the number of seeded wells corresponding to the number of processed hearts. After 24 h of incubation, the growth medium was replaced, and cells were cultured for 3-7 days. Large numbers of robustly contracting cardiomyocyte clusters were used for experiments described below. Hypoxic condition was created by incubating cardiomyocytes in a Controlled Atmosphere Chamber (PASS USA, Lansing, MI, USA) with an atmosphere of 5% CO 2 /95% N 2 at 37 C. Cells plated in six-well plates and cultured to 80-90% confluence were transferred to the chamber and incubated in oxygen-depleted medium for 0.5-7 days.
In other experiments, primary cardiomyocytes were exposed to hypoxia for 0.5-2 days in the presence or absence of PCSK9 inhibitor Pep2-8 or an EGF-A-based inhibitor (each 10 mM), HIF-1a inhibitor dimethylbisphenol A (100 mM; Santa Cruz, Dallas, TX, USA), and ROS inducers pyocyanin (50 lM) and antimycin A (100 lM) or ROS inhibitors diphenylene-iodonium chloride (DPI) and apocynin (each 20 mM) (Sigma). To mimic PCSK9 overexpression and release, cardiomyocytes were incubated with recombinant mouse PCSK9 protein (0.5, 1, and 2 mg/mL; Life Technologies, Grand Island, NY, USA) for 2 days in the presence of hypoxia.
Assessment of cardiomyocyte metabolic activity
Cell metabolic activity was assessed using MTT assay kit (ATCC) according to the manufacturer's instructions. Absorbance at 570 nm was measured using a microplate reader.
2.7 ELISA for PCSK9, TNF-a, and LDL-cholesterol PCSK9 secretion was measured in mouse sera or cell culture media using a Mouse PCSK9 ELISA kit (MBL International, Nagoya, Japan). TNF-a was measured in mouse serum samples, as an indicator of inflammatory state, with TNF-a ELISA kit (Abcam, San Francisco, CA, USA). LDLcholesterol (LDL-C) was measured by Mouse Low Density Lipoprotein Cholesterol ELISA Kit (MyBioSource, Inc., San Diego, CA, USA).
siRNA transfection of primary mouse cardiomyocytes
siRNA duplexes corresponding to mice HIF-1a and PCSK9 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). In order to knockdown gene expression, cardiomyocytes were transfected with 20 nM of each siRNA for 24 h with siRNA transfection reagent (Santa Cruz). The medium was replaced with normal culture medium, and cells were then treated with hypoxia for indicated time. As control, cells were transfected with sequence scrambled siRNA control (Santa Cruz). Cell lysates were utilized for ELISA or western blot analysis to verify efficacy of protein knockdown by siRNA.
Western blot
The border zone between the ischaemic and remote normal area was carefully dissected under the microscope. Protein from hearts and cardiomyocytes were purified with RIPA Lysis Buffer System (Santa Cruz, CA, USA) and loaded onto 12% Mini-PROTEAN V R TGX TM Precast Gel (Bio-rad, CA, USA) for electrophoresis. The size-separated proteins were then transferred to Hybond ECL Nitrocellulose Membranes (GE Healthcare, NJ, USA). After blocking with 5% BSA buffer for 1 h, the membranes were incubated with primary antibody at 1:1000 dilution overnight at 4 C. After washing with PBS containing 0.1% Tween-20, membranes were incubated with secondary antibody for 1 h and signals were detected with Pierce ECL western blotting substrate (Thermo Scientific, IL, USA). Intensity quantification of the bands were obtained with Image J software and normalized to b-actin. Antibodies directed at PCSK9 (ab31762), p-AMPKa (ab133448), p-LKB1 (ab63473), LKB1 (ab15095), and CaMKK (ab80066) were purchased from Abcam (San Francisco, CA, USA). Antibodies directed at LC3 (4108), Beclin-1 (3738), and ATM (2873) were purchased from Cell signalling (Danvers, MA, USA). Antibodies directed at p-ATM (05-740) was purchased from MilliporeSigma (Burlington, MA, USA). In in vitro studies, bafilomycin A1 (Sigma-Aldrich) was used to study if the change in the autophagy-related protein LC3-II was due to enhanced autophagosome synthesis. Bafilomycin A1 is known to inhibit the vacuolar type H þ -ATPase and prevent acidification of autophagosomes and lysosomes, leading to inhibition of LC3-II degradation and increase in LC3-II levels. In these experiments, cells were treated with or without hypoxia or mPCSK9 in the presence or absence of 100 nM bafilomycin A1 for the indicated time.
In vivo, mice were injected intraperitoneal with bafilomycin A1 (5 lmol/kg in DMSO) or vehicle control (DMSO) and sacrificed 2 h later. The differences of myocardial LC3-II protein levels between bafilomycin A1 and vehicle treated mice reflect autophagic flux. 
Measurement of cellular ROS by flow cytometry
Immunohistochemical staining
For immunohistochemical analyses, 5 mm thick sections of the heart were stained with different antibodies and analysed using Mouse/Rabbit Specific HRP/3,3 0 -diaminobenzidine detection immunohistochemistry kit (Abcam, San Francisco, CA, USA).
Collection and staining of human heart tissues
Human ischaemic heart blocks were obtained from the the hearts were immunostained for PCSK9 and LC3. Image J was used to quantify expression of PCSK9 and LC3 with at least nine different areas in the same staining figure.
Statistical analysis
Data are presented as mean ± standard deviation (SD). Statistical analysis was performed with SPSS 11.5 software. Multiple comparisons were analysed by one-way analysis of variance (ANOVA) but not post-test. Pvalues of <0.05 were considered to be significant.
Results
LCA ligation, cardiac function, PCSK9, and autophagy in the ischaemic heart
LCA ligation resulted in extensive infarct and a marked decline in cardiac contractile function. LV shortening fraction (SF), measured by echocardiography, declined from 61 ± 7% to 25 ± 4% (mean ± SD) (P < 0.01) at 1 week after LCA ligation ( Figure 1A ). The LV fractional shortening appeared to improve somewhat at 2, 3, and 4 weeks after LCA ligation, but it was still significantly lower than at baseline. Infarcted and remote normal areas were characterized in mice hearts subjected to LCA ligation by gross visualization of the hearts and H&E staining of multiple sections. Expression of PCSK9 was studied at different time points (1, 2, 3, and 4 weeks) after LCA ligation. As shown in Figure 1B , there was intense expression of PCSK9 in the myocardium, mostly in the border zone between the infarct area and the normal area of the heart. The immunohistochemistry data were confirmed by western blotting. qPCR and western blot showed that PCSK9 expression was highest at 1 week after LCA ligation and gradually declined thereafter. Even at 4 weeks after LCA ligation, it was modestly but significantly elevated compared to the sham ischaemia group ( Figure 1C) .
Next, we assessed autophagy in response to ischaemia by measuring expression of LC3 and beclin-1. The conversion of LC3-I into LC3-II is an essential step in autophagosome formation, and the abundance of LC3-II correlates with the number of autophagosomes; while beclin-1 is a wellknown key regulator of autophagy. 6 Autophagy signals increased almost 10-fold in the ischaemic heart, with highest expression at 1 week after LCA ligation, and then gradually decreased at 2-4 weeks after LCA ligation ( Figure 1D ). We also measured protein levels of p62, a selective substrate of autophagy; autophagic flux leads to a decline in p62 expression. 18 We observed that p62 expression was minimal at 1 week after LCA ligation and then increased substantially. Immunohistochemical staining (1 week post-LCA ligation) showed that LC3 was maximally expressed in the border zone between the infarct area and the remote healthy area ( Figure 1E ). The aforementioned data suggest that mice hearts during ischaemic stress express PCSK9 and develop autophagy-mostly in the region bordering the infarct area. Both PCSK9 expression and autophagy activity appear to increase at 1 week after LCA ligation and decline in parallel thereafter, suggesting a correlation of the two phenomena.
Because PCSK9 expression and development of autophagy were maximal at 1 week after LCA ligation, we chose this time point for subsequent experiments.
PCSK9 inhibition, infarct size, and autophagy in vivo
To investigate the role of PCSK9 in the determination of infarct size, cardiac contractile function, and development of autophagy, we treated mice with two different PCSK9 inhibitors, a 13-amino acid linear peptide Pep2-8 (the smallest PCSK9 inhibitor) and an EGF-A peptide. 19 Other studies were done in PCSK9 gene knockout (PCSK9 -/-) mice. Pre-treatment of mice with either Pep2-8 or EGF-A significantly decreased ischaemia-induced PCSK9 release, which was evident on measurement of PCSK9 in serum by ELISA (Figure 2A) . Importantly, inhibition of PCSK9 improved cardiac contractile function by about 25% and reduced infarct size by 20-30% (both P < 0.01 vs. ischaemia in untreated hearts, Figure 2B and C). Pre-treatment with either Pep2-8 or EGF-A also reduced PCSK9 expression in the heart by about 50% ( Figure 2D ). Western blot ( Figure 2D) showed that autophagy activity (indicated as expression of LC3, p62 and beclin-1, and autophagic flux) in the ischaemic heart was inhibited by pre-treatment of mice with either Pep2-8 or EGF-A. As shown in Figure 2E , treatment with Pep2-8 or EGF-A had no significant effect on LDL-C levels compared with saline treatment.
Similar to the observations in mice treated with PCSK9 inhibitors, mice with PCSK9 gene deletion showed improved cardiac function and smaller infarct size after LCA ligation (both P < 0.01 vs. ischaemia in wild-type mice hearts). The thinning of the LV wall in the area surrounding the infarct zone was also much less than in the wild-type mice subjected to LCA ligation. Notably, there was no difference in body weight of wild-type and PCSK9
-/-mice ( Figure 3A ).
These findings, based on studies in mice with PCSK9 inhibition (by two different chemical inhibitors or gene deletion), indicate that attenuation of PCSK9 results in a significant improvement in cardiac function and infarct size ( Figure 3B and C) . These mice ( Figure 3D and E) also show a significant decrease in autophagy activity. These observations imply a strong association between PCSK9 expression and development of autophagy in the ischaemic heart.
Role of inflammation and hypoxia in the induction of PCSK9 and autophagy
Inflammation is a characteristic feature of myocardial infarction. 19 Proinflammatory state is characterized by release of cytokines such as TNFa (a central regulator of inflammation). 20 In this study, we confirmed that serum levels of TNF-a were indeed elevated several-fold following LCA ligation, indicating a systemic inflammatory state ( Figure 4A ). In order to study if inflammation influences the expression of PCSK9 in the ischaemic heart, we treated primary mouse cardiomyocytes with synthetic TNF-a (10-40 ng/mL). There was only a small amount of PCSK9 in the cardiomyocyte supernatants in the basal state, but TNF-a treatment resulted in a robust release of PCSK9, and the release was TNF-a concentration-dependent ( Figure 4B) .
Next, we focused on the role of hypoxia to which the heart tissue is exposed during coronary artery occlusion. First, we studied the effect of hypoxia on the viability of cardiomyocytes. As shown in Figure 4C , cell viability decreased slightly as the period of hypoxia was increased from 0.5 to 2 days, but it declined rapidly thereafter. In subsequent experiments, we maintained the duration of hypoxia at 2 days.
As shown in Figure 4D , PCSK9 expression increased when cardiomyocytes were exposed to hypoxia. Expression of PCSK9 was dependent on the duration of hypoxia (0.5-2 days). Hypoxia also increased autophagy flux and LC3 and beclin-1 expression ( Figure 4E and F) . Bnip3 is known to be induced by hypoxia, and autophagy has been shown to be protective against Bnip3-induced autophagy and cell death. 21 We, therefore, studied the expression of Bnip3 along with PCSK9 and autophagy and observed it to be increased during hypoxia ( Figure 4G) . Thus, the appearance of PCSK9 and autophagy during hypoxia seemed to parallel.
PCSK9, infarct size, and autophagy Hypoxia inducible factor-1 a (HIF-1a) is a critical regulator of cellular and systemic responses to low oxygen levels, and plays crucial role in the development of myocardial infarction. 21 Previously, we reported that there is a crosstalk between PCSK9 and LOX-1. 4 Crucet et al. 21 showed that hypoxia regulates ox-LDL uptake in macrophages via LOX-1. We, therefore, posited that HIF-1a may play an important role in PCSK9 expression and autophagy during ischaemia. We examined this hypothesis in primary cardiomyocytes by utilizing two different approaches, first the PCSK9 levels in serum (measured by ELISA) were markedly lower in HIF-1a
-/-mice and in WT mice treated with dimethyl-bisphenol A compared with WT mice, all mice subjected to LCA ligation. Of note, the PCSK9 levels at baseline were similar in both WT and HIF-1a -/-mice ( Figure 5A ). Western blot also showed that deletion of HIF-1a markedly reduced the expression of PCSK9, LC3, and beclin-1 during ischaemia. Treatment of WT mice with dimethyl-bisphenol A also reduced autophagy signals ( Figure 5B ). Further studies were performed to confirm the role of HIF-1a in primary cardiomyocytes. As expected, hypoxia significantly induced HIF-1a expression ( Figure 5C ). Both ELISA ( Figure 5C ) and western blot ( Figure 5D ) showed that the expression/release of PCSK9 increased markedly in response to hypoxia, and this phenomenon was almost completely inhibited by pre-treatment of cardiomyocytes with HIF-a siRNA or dimethyl-bisphenol A. As shown in Figure 5E and F, expression of LC3-II and beclin-1 increased in cardiomyocytes exposed to hypoxia. Autophagic flux increased during hypoxia. These phenomena were significantly attenuated in cardiomyocytes transfected with HIF-1a siRNA or treated with dimethyl-bisphenol A.
Relationship between PCSK9 release and the development of autophagy
Based on the aforementioned observations, we postulated that there may be a link between PCSK9 release and autophagy during ischaemia. We confirmed this link in two ways-by up-regulation of PCSK9 and by its down-regulation. In the first approach, cardiomyocytes were treated with recombinant mouse PCSK9 protein (mPCSK9, 0.5-2 ng/mL), and in the second approach, cardiomyocytes were transfected with PCSK9 siRNA or with a chemical PCSK9 inhibitor (Pep2-8). In keeping with our postulate, mPCSK9 in a dose-dependent manner induced the expression of LC3-II and beclin-1, as well as autophagic flux ( Figure 6A and B) . On the other hand, inhibition of PCSK9 in cardiomyocytes by siRNA transfection or treatment with Pep2-8 markedly reduced the expression of LC3-II and beclin-1, as well as autophagic flux (Figure 6C and D) . Of note, PCSK9 siRNA transfection efficiency was confirmed by western blot (Figure 6D, inset) .
These observations clearly demonstrate that PCSK9 secretion by cardiomyocytes causes the development of autophagy.
Signalling between PCSK9 and autophagy
AMP-activated protein kinase (AMPK) is a key energy sensor that regulates cellular metabolism to maintain energy homeostasis. 19 AMPK is maximally active when phosphorylated, and its activity is required to induce autophagy in response to many stressors in mammalian cells such as hypoxia, ischaemia, and ROS. 20 Since PCSK9 regulates LDLr and also plays a key role in energy homeostasis, we posited that AMPK may be involved in PCSK9-mediated autophagy during hypoxia. As shown in Figure 7A and B, mPCSK9 enhanced phospho-AMPKa levels in a dosedependent manner, whereas PCSK9 inhibition by siRNA transfection and Pep2-8 reduced phospho-AMPKa levels, indicating that AMPKa activation plays a key role in PCSK9-mediated development of autophagy. Phosphorylation of LKB1 (liver kinase B1), a Ser/Thr kinase, is known to favour AMPK activation. In addition to LKB1, CaMKK (Ca 2þ /calmodulin-dependent protein kinase) has been shown to play a major role in AMPK activation response to elevated calcium levels. 21 We investigated the role of PCSK9 in these two major upstream kinases during hypoxia. As shown in Figure 7C , mPCSK9 enhanced, and PCSK9 inhibition reduced, the expression of phospho-LKB1. However, neither PCSK9 upregulation nor its PCSK9 inhibition had any effect on CaMKK expression ( Figure 7D ), indicating that only LKB1 plays a role in PCSK9-mediated AMPK activation.
Ataxia-telangiectasia mutated serine/threonine kinase (ATM) lies upstream of LKB1 and has been shown to phosphorylate AMPKa through regulation of LKB1 in response to DNA damage. A previous study from our laboratory 3 showed that mitochondrial DNA damage plays a role in LPS-induced PCSK9 expression. We posited that ATM signalling might be involved in PCSK9-mediated autophagy. We examined this postulate in this study. As shown in Figure 7E , mPCSK9 enhanced, while PCSK9 inhibition reduced, the expression of phosphorylated ATM. ROS have been shown to induce the expression of both ATM and PCSK9. We posited that ROS may play a role in PCSK9-ATM-LKB1-AMPK signalling leading to autophagy. We studied this postulate and found that ROS inhibitors DPI and apocynin significantly decreased hypoxia-induced p-ATM expression ( Figure 7F) . Further, mPCSK9-induced ROS generation in a dose-dependent manner ( Figure 7G) , while PCSK9 inhibition (by siRNA transfection or pre-treatment with Pep2-8) reduced ROS generation ( Figure 7H) . Interestingly, both ROS inducer pyocyanin and superoxide inducer antimycin A induced PCSK9 expression ( Figure 7I) , and ROS inhibitors DPI and apocynin markedly inhibited PCSK9 expression (Figure 7J) , indicating that there is a bidirectional Primary cardiomyocytes were exposed to hypoxia for 2 days in the presence or absence of mPCSK9, PCSK9 siRNA, or Pep2-8. NC, negative control; Baf A1, Bafilomycin A1. Western blots for LC3 are representative of multiple independent experiments; and graphs show data for beclin-1 from each experiment. These in vitro data were obtained from several independent experiments (n = 5). Data are presented as mean ± SD. Multiple comparisons made by one-way ANOVA. *P < 0.05 vs. control, **P < 0.05 vs. hypoxia.
PCSK9, infarct size, and autophagy crosstalk between ROS and PCSK9. Measurement by ELISA of PCSK9 secretion in the cardiomyocyte supernatant also confirmed the role of ROS in PCSK9 regulation ( Figure 7K ). It is of note that hypoxia consistently induced ROS generation, and the ROS generation was dependent on the duration of hypoxia to which cardiomyocytes were exposed ( Figure 7L ). This signalling is summarized in Figure 7M. 3.6 Role of LDLr and ROS in PCSK9-mediated autophagy and cell viability PCSK9 protein directs the LDLr to the lysosome for degradation and regulates its downstream signalling with an important role for ROS in this process. We asked if PCSK9-mediated development of autophagy is dependent on the presence of LDLr. To clarify this, primary cardiomyocytes were separated from new born wild-type and LDLr -/-mice. As shown in Supplementary material online, Figure S1A , expression of both LC3 and beclin-1 as well as autophagic flux in LDLr -/-cardiomyocytes in response to mPCSK9 (0.5-2 mg/ml) was much less than in wild-type mice cardiomyocytes (P < 0.05). In addition, ROS inducers pyocyanin and antimycin A significantly enhanced, and ROS inhibitors DPI and apocynin reduced, mPCSK9-induced expression of LC3 and beclin-1 as well as autophagic flux (see Supplementary material online, Figure S1B ). We also observed that viability of cardiomyocytes (from wild-type mice) decreased in response to mPCSK9, and PCSK9 inhibition (by siRNA transfection or treatment with Pep2-8) reduced the loss of cell viability. The loss of viability in response to mPCSK9 was much less in cardiomyocytes from LDLr -/-mice, and PCSK9 inhibition almost completely blocked mPCSK9-induced cell death (see Supplementary material online, Figure S1C ). Of note, ROS inducers pyocyanin and antimycin A decreased cell viability beyond that caused by mPCSK9, while ROS inhibitors DPI and apocynin enhanced cell survival despite exposure of cells to mPCSK9 (see Supplementary material online, Figure S1D ).
PCSK9 and autophagy in ischaemic human heart
To examine if the association of PCSK9 and autophagy is also present in humans, we checked multiple heart sections from eight patients who had died of acute myocardial infarction (1-7 days post-myocardial infarction). Immunohistochemical staining showed that both PCSK9 and LC3 were highly expressed in the border zone between the ischaemia and remote normal areas in each heart (see Supplementary material online, Figure S2A and B). These observations are consistent with the findings in mice.
Discussion
There is intense interest in the role of PCSK9 in hypercholesterolaemia and atherosclerotic cardiovascular disease. 1 Although the major source of PCSK9 is known to be liver and to a small extent kidneys and intestine, there is emerging evidence that PCSK9 is also synthesized in vascular smooth muscle cells exposed to low shear stress or pro-inflammatory stimuli. [2] [3] [4] [5] Ferri et al. 22 recently showed that PCSK9-null mice are protected from neointima formation in response to perivascular carotid collar placement, suggesting that vascular smooth muscle cell-derived PCSK9 contributes to steps leading to atherosclerosis, which is considered an inflammatory disease. Herein, we show for the first time that PCSK9 is expressed in the ischaemic heart and the expression is highest in the zone bordering the infarcted areas. The expression of PCSK9 is maximal early (1 week) after LCA ligation and begins to decline thereafter. The expression of PCSK9 is associated with the development of autophagy, and the degree of autophagy parallels PCSK9 expression, suggesting a link between PCSK9 expression/release and development of autophagy. A strong evidence for the link between PCSK9 and autophagy came from studies in mice treated with PCSK9 inhibitors (Pep2-8 and EGF-A) or in mice lacking PCSK9 gene and subjected to LCA ligation. In these mice, autophagic signals were decreased despite LCA ligation.
We also show that PCSK9 release from the myocardium subjected to ischaemic insult determines, at least in part, the infarct size and cardiac function. This concept was examined in two different ways: use of two chemical inhibitors of PCSK9 and use of mice lacking PCSK9 gene. It became readily apparent that mice with PCSK9 inhibition/absence had improved cardiac function and smaller infarct size. Importantly, there appeared to be a correlation between release/expression of PCSK9 and infarct size, as well as cardiac function. Further, the development of autophagy was also significantly attenuated in mice treated with PCSK9 inhibitors, confirming a role of PCSK9 in signalling of the autophagic response-which may relate to determination of eventual infarct size.
The relationship between PCSK9 expression and autophagy was examined in detail in cultured neonatal mice cardiomyocytes. Inflammation and hypoxia are uniformly present in the ischaemic heart. We observed that TNF-a induced both PCSK9 expression and autophagy. Exposure of cardiomyocytes to hypoxia also resulted in PCSK9 expression and autophagy. The effects of hypoxia were mediated via HIF-1a, since its inhibition by a specific siRNA significantly reduced the expression of both PCSK9 and autophagy. Further, hypoxia led to ROS generation. The hypoxia-induced loss of viability of cardiomyocytes was enhanced by ROS inducers and blocked by ROS inhibitors. Further, we observed that ROS stimulators enhanced PCSK9 expression and ROS inhibitors blocked PCSK9 expression. Recombinant mPCSK9 enhanced ROS generation, and PCSK9 inhibition reduced ROS generation. These observations suggest a bidirectional crosstalk between ROS and PCSK9.
The link between PCSK9 and autophagy was studied by multiple approaches. First, treatment of primary cardiomyocytes with recombinant mPCSK9 resulted in a prompt expression of LC3-II and beclin-1 expression, well-known markers of autophagy. 6 Second, the inhibition of PCSK9 (by transfection of cardiomyocytes with siRNA directed at PCSK9 or treatment of cardiomyocytes with a chemical inhibitor Pep2-8) resulted in the attenuation of LC3-II and beclin-1 expression.
Other studies in primary cardiomyocytes were performed to examine if PCSK9-autophagy link during ischaemia is dependent on the status of LDLr. Cardiomyocytes from LDLr-null mice showed much less autophagic response to recombinant mPCSK9, suggesting dependence of the phenomenon on the presence of LDLr. Yet, other studies were performed to determine if PCSK9-induced loss of cardiomyocyte viability was dependent on the presence of LDLr. We observed that the adverse effect of PCSK9 on cardiomyocyte viability was also dependent on the presence of LDLr. Nonetheless, the dependence of the effect of PCSK9 on LDLr raises an interesting question: if PCSK9 inhibition is cardioprotective through degrading LDLr, then why would the LDLr-null mouse be protected. Based on our and others' work, [2] [3] [4] [5] it appears that PCSK9 not only degrades LDLr, but also has many other functions such as induction of ROS, regulation of inflammatory response, and other lipid receptors. PCSK9 may also act as a PAMP/DAMP to up-regulate inflammatory signalling and autophagy. 23 We studied PCSK9 and autophagy expression in multiple heart sections from patients who had died of acute myocardial infarction (1-7 days post-myocardial infarction). Similar to the data in mice with coronary ligation, both PCSK9 and LC3 were highly expressed in the border zone between the ischaemic and remote normal areas. Unfortunately, the archived tissues did not permit us to study if PCSK9 mRNA levels were also elevated in these tissues.
PCSK9 expression in the heart during ischaemia is a relatively novel observation. Zhang et al. 24 demonstrated a drastic increase in hepatic PCSK9 expression and plasma PCSK9 levels during the acute stage of myocardial infarction in rats. The Ottawa Heart Genomics study and the Emory Cardiology Biobank study also showed significant elevation in plasma PCSK9 levels in patients with acute myocardial infarction. 25 Also, plasma level of PCSK9 appears to be an independent predictor of outcome in patients with coronary disease, hypertension, and diabetes. [26] [27] [28] [29] This study suggests that cardiomyocytes may be an important source of PCSK9 during myocardial ischaemia, but liver may have been an important source of PCSK9. Our in vitro studies clearly show that hypoxia and inflammation, characteristic features of ischaemia, trigger several-fold increase in PCSK9 expression. Autophagy is an important intracellular process in regulating cardiac homeostasis in response to stress. Autophagy is a critical part of normal cell differentiation and morphogenesis. 30 Autophagy has been demonstrated to have a protective role in cardiac response to ischaemia by eliminating damaged mitochondria and preventing apoptosis initiation. Albeit beneficial, unregulated autophagy can be deleterious and result in cell death. 30 Several investigators have demonstrated a dramatic increase in autophagy during the reperfusion phase of cardiac ischaemia. [31] [32] [33] [34] Whether this increase elicits a protective or a deleterious effect on the myocardium is a matter of debate. Kanamori et al. 35 demonstrated an increase in autophagy activity in sub-acute and chronic stages of cardiac ischaemia in a mice model of myocardial infarction. Similar to our observations, autophagy activity was prominent in the border zone of the infarct compared to remote areas of the myocardium. However, with induction of chronic ischaemia, autophagy activity increased in the remote myocardium. In their studies, inhibition of autophagy led to adverse cardiac remodelling following myocardial infarction, suggesting a dynamic role of autophagy in the determination of infarct size and cardiac contractile function. PCSK9 release early after onset of myocardial ischaemia may be a protective response by stimulating autophagic activity in the short run. However, sustained PCSK9 release and autophagic response during hypoxia may have deleterious effect by inducing cell self-digestion and cell death. It is apparent that PCSK9 can regulate autophagy during ischaemia, and we are not sure if PCSK9-mediated autophagy is deleterious or beneficial; this aspect needs to be further investigated. Further studies will be needed to determine the role of PCSK9 in the determination of infarct size and cardiac contractile function after coronary occlusion. These concepts are summarized in Supplementary material online, Figure S3 .
Some of the other unresolved issues are the role of Pep2-8 and EGF-A, which compete with PCSK9 binding to LDLr. Usually, Pep2-8 and EGF-A do not regulate PCSK9 secretion. Nonetheless, we observed that Pep2-8 and EGF-A down-regulated ischaemia-induced PCSK9 expression. Further, it is possible that PCSK9 secreted by the ischaemic heart may be different from the circulating PCSK9 and may have different functions. Lastly, primary cardiomyocytes from newborn mice may not reflect events in adult cardiomyocytes, but these cell types have been used to study physiological and pathological changes by a number of investigators. [36] [37] [38] Of note, the data obtained in the neonatal mouse cardiomyocytes exposed to hypoxia or TNF-a in vitro affirmed the events taking place in the in vivo state. PCSK9 is mainly secreted by the liver and released into the blood. Circulating PCSK9 levels correlate with LDL-c levels. LDL-c is prone to oxidation (formation of ox-LDL) by ROS and oxidative ions. High concentrations of ox-LDL are cytotoxic, activate autophagy, 39 and regulate infarct size via LOX-1 (ox-LDL receptor). 40 There is a crosstalk between PCSK9 and LOX-1. 4 Based on this background, it is reasonable to assume that PCSK9 regulates autophagy and infarct size indirectly by modulating LDL-c levels.
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Supplementary material is available at Cardiovascular Research online.
